78
Participants
Start Date
May 25, 2023
Primary Completion Date
June 30, 2025
Study Completion Date
December 31, 2025
AK104
AK104 (6mg/kg) on day 1, IV, Q2W
AK104
AK104 (10mg/kg) on day 1, IV, Q2W
Gemcitabine
Gemcitabine (1000mg/m2) on days 1, 8 and 15, IV, Q4W
Nab-Paclitaxel
Nab-Paclitaxel (125mg/m2) on days 1, 8 and 15, IV, Q4W
Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
RECRUITING
Peking Union Medical College Hospital, Beijing
RECRUITING
Shanghai Changhai Hospital, Shanghai
RECRUITING
Shandong Cancer Hospital, Jinan
RECRUITING
Zhejiang Cancer Hospital, Hangzhou
RECRUITING
Sun Yat-sen University Cancer Center, Guangzhou
RECRUITING
Union Hospital Tongji Medical College Huazhong University of Science And Technology, Wuhan
RECRUITING
Zhejiang Provincial People's hospital, Hangzhou
Lead Sponsor
Akeso
INDUSTRY